Development and stability of an oral suspension of procarbazine in pediatrics
Many drugs used in pediatric oncology are not labeled and adapted for pediatric use, such as caps of procarbazine to treat gliomas in children under 6 years old. Indeed, pediatric patients present difficulties to swallow these caps and it can lead to major observance problems. To provide a solution to this situation, we propose the development of an oral procarbazine suspension.
Suspension was produced from the commercial capsules powder of procarbazine 50 mg, mixed with excipients, specifically selected for children. The physical and chemical stability of this presentation was assessing with a specific RP-HPLC method and degradation products were study in forced degradation conditions according to the French and the European recommendations. A 10 mg/mL suspension was formulated and divided into single-dose syringes, in order to secure administration.
We formulated a new dosage form of procarbazine to ensure an accurate and safe dose for children administration.